Cargando…

Bile acids contribute to the development of non-alcoholic steatohepatitis in mice

BACKGROUND & AIMS: Through FXR and TGR5 signaling, bile acids (BAs) modulate lipid and glucose metabolism, inflammation and fibrosis. Hence, BAs returning to the liver after enteric secretion, modification and reabsorption may contribute to the pathogenesis of non-alcoholic steatohepatitis (NASH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gillard, Justine, Clerbaux, Laure-Alix, Nachit, Maxime, Sempoux, Christine, Staels, Bart, Bindels, Laure B., Tailleux, Anne, Leclercq, Isabelle A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604813/ https://www.ncbi.nlm.nih.gov/pubmed/34825156 http://dx.doi.org/10.1016/j.jhepr.2021.100387

Ejemplares similares

Impact of L-ornithine L-aspartate on non-alcoholic steatohepatitis-associated hyperammonemia and muscle alterations
por: Pichon, Camille, et al.
Publicado: (2022)

Bile Acid Dysregulation Is Intrinsically Related to Cachexia in Tumor-Bearing Mice
por: Thibaut, Morgane M., et al.
Publicado: (2021)

Enterohepatic Takeda G-Protein Coupled Receptor 5 Agonism in Metabolic Dysfunction-Associated Fatty Liver Disease and Related Glucose Dysmetabolism
por: Gillard, Justine, et al.
Publicado: (2022)

Biological tuners to reshape the bile acid pool for therapeutic purposes in non-alcoholic fatty liver disease
por: Gillard, Justine, et al.
Publicado: (2023)

Myosteatosis rather than sarcopenia associates with non‐alcoholic steatohepatitis in non‐alcoholic fatty liver disease preclinical models
por: Nachit, Maxime, et al.
Publicado: (2020)

Liver Regeneration: Different Sub-Populations of Parenchymal Cells at Play Choreographed by an Injury-Specific Microenvironment
por: Manco, Rita, et al.
Publicado: (2018)

Rationale of adding muscle volume to muscle fat infiltration in the definition of an adverse muscle composition is unclear
por: Nachit, Maxime, et al.
Publicado: (2021)

AdipoRon enhances healthspan in middle‐aged obese mice: striking alleviation of myosteatosis and muscle degenerative markers
por: Selvais, Camille M., et al.
Publicado: (2022)

Role of ciliary dysfunction in a new model of obesity and non-alcoholic steatohepatitis: the foz/foz mice
por: Poekes, Laurence, et al.
Publicado: (2014)

Inhibition of connexin hemichannels alleviates non-alcoholic steatohepatitis in mice
por: Willebrords, Joost, et al.
Publicado: (2017)

Bile Acids and Metabolic Regulation: Mechanisms and clinical responses to bile acid sequestration
por: Staels, Bart, et al.
Publicado: (2009)

Rifaximin Ameliorates Non-alcoholic Steatohepatitis in Mice Through Regulating gut Microbiome-Related Bile Acids
por: Jian, Jie, et al.
Publicado: (2022)

Impact of Vancomycin Treatment and Gut Microbiota on Bile Acid Metabolism and the Development of Non-Alcoholic Steatohepatitis in Mice
por: Kasai, Kaichi, et al.
Publicado: (2023)

Bile acid metabolism regulated by the gut microbiota promotes non-alcoholic steatohepatitis-associated hepatocellular carcinoma in mice
por: Yamada, Shoji, et al.
Publicado: (2018)

Soaping Up Type 2 Diabetes With Bile Acids?: The Link Between Glucose and Bile Acid Metabolism in Humans Tightens: Quality Matters!
por: Staels, Bart, et al.
Publicado: (2013)

Carvedilol impairs bile acid homeostasis in mice: implication for nonalcoholic steatohepatitis
por: Lastuvkova, Hana, et al.
Publicado: (2023)

Medicinal Formula Huazhi-Rougan Attenuates Non-Alcoholic Steatohepatitis Through Enhancing Fecal Bile Acid Excretion in Mice
por: Li, Chunlin, et al.
Publicado: (2022)

Lactiplantibacillus plantarum LPJZ-658 Improves Non-Alcoholic Steatohepatitis by Modulating Bile Acid Metabolism and Gut Microbiota in Mice
por: Liu, Liming, et al.
Publicado: (2023)

Bile Acid Sequestrants for Lipid and Glucose Control
por: Staels, Bart, et al.
Publicado: (2010)

Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis
por: Luo, Yi, et al.
Publicado: (2021)

Contributions of Streptococcus mutans Cnm and PA antigens to aggravation of non-alcoholic steatohepatitis in mice
por: Naka, Shuhei, et al.
Publicado: (2016)

Myeloid DLL4 Does Not Contribute to the Pathogenesis of Non-Alcoholic Steatohepatitis in Ldlr(-/-) Mice
por: Jeurissen, Mike L. J., et al.
Publicado: (2016)

Fetuin-A in Activated Liver Macrophages Is a Key Feature of Non-Alcoholic Steatohepatitis
por: Etienne, Quentin, et al.
Publicado: (2022)

Conophylline inhibits non-alcoholic steatohepatitis in mice
por: Nakade, Yukiomi, et al.
Publicado: (2017)

Atorvastatin Modulates Bile Acid Homeostasis in Mice with Diet-Induced Nonalcoholic Steatohepatitis
por: Lastuvkova, Hana, et al.
Publicado: (2021)

Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPARα
por: Liang, Ning, et al.
Publicado: (2019)

Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression
por: Loyer, Xavier, et al.
Publicado: (2016)

Best Poster Award – Second Prize: Bile Acids as Novel Vascular Signalling Molecules and Therapeutic Target
por: Jomard, A, et al.
Publicado: (2020)

Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice
por: Hartmann, Phillipp, et al.
Publicado: (2022)

Cell-derived microparticles in atherosclerosis: biomarkers and targets for pharmacological modulation?
por: Baron, Morgane, et al.
Publicado: (2012)

Publisher Correction: Microbiota analysis and transient elastography reveal new extra-hepatic components of liver steatosis and fibrosis in obese patients
por: Lanthier, Nicolas, et al.
Publicado: (2021)

Microbiota analysis and transient elastography reveal new extra-hepatic components of liver steatosis and fibrosis in obese patients
por: Lanthier, Nicolas, et al.
Publicado: (2021)

Gut microbiota contribution to hepatocellular carcinoma manifestation in non-alcoholic steatohepatitis
por: Liakina, Valentina, et al.
Publicado: (2022)

Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice
por: Salic, Kanita, et al.
Publicado: (2019)

Differential Lipidomics, Metabolomics and Immunological Analysis of Alcoholic and Non-Alcoholic Steatohepatitis in Mice
por: Dorochow, Erika, et al.
Publicado: (2023)

Liver Steatosis and Steatohepatitis Alter Bile Acid Receptors in Brain and Induce Neuroinflammation: A Contribution of Circulating Bile Acids and Blood-Brain Barrier
por: Fiaschini, Noemi, et al.
Publicado: (2022)

Combined alcoholic and non-alcoholic steatohepatitis
por: Ntandja Wandji, Line Carolle, et al.
Publicado: (2020)

Berberine ameliorates non-alcoholic steatohepatitis in ApoE(−/−) mice
por: Yang, Jin, et al.
Publicado: (2017)

Inflammation‐induced cholestasis in cancer cachexia
por: Thibaut, Morgane M., et al.
Publicado: (2020)

NASH-related increases in plasma bile acid levels depend on insulin resistance
por: Grzych, Guillaume, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2cj2i94enjjlk8953p8rvoek2f